Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children
AbstractIn 1992, Egypt adopted a hepatitis B vaccine schedule at 2, 4 and 6 months of age. We evaluated the long-term immunogenicity and efficacy of vaccination using this schedule in 180 children whose time lapse since last vaccination varied between 1 month and 5 years. None of the participants had clinical hepatitis, HBsAg was not detected in any participant and all but one had negative results for anti-HBc test. Although a high seroprotection rate [93.3%] was elicited 1 month after vaccination, there were low initial anti-HBs concentrations and both declined rapidly over time. Thus, the short interval [2 months] between the second and third doses of vaccine is less desirable in the long term. We recommend booster inoculations for all previously vaccinated children and a new vaccination schedule at 1, 2 and 9 months
El Sawy, I.H. & Mohamed, O.N. (1999). Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. http://www.who.int/iris/handle/10665/118780
EMHJ - Eastern Mediterranean Health Journal, 5 (5), 922-932, 1999
MetadataShow full item record
Showing items related by title and MeSH subject.
A collaborative study of the proposed international reference preparation for hepatitis B vaccine containing plasma-derived hepatitis B surface antigen (HBsAg / by Morag Ferguson, Valerie Seagroat and Geoffrey C. Schild Ferguson, Morag; Seagroatt, Valerie; Schild, Geoffrey Christopher; World Health Organization. Biologicals Unit (WHO/BS/86.1525, Rev.1. Unpublished, 1986)